← All trials
NCT04937452
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Apr 1, 2024
- First posted
- Jun 24, 2021
- Last posted
- Jun 24, 2021
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- I.R.C.C.S. Fondazione Santa LuciaLead sponsor
- I.R.C.C.S. Fondazione Santa LuciaReponsible party - principal investigator
- I.R.C.C.S. Fondazione Santa LuciaOverall official - principal investigator
- I.R.C.C.S. Fondazione Santa LuciaStudy director
- Alzheimer’s Drug Discovery FoundationCollaborator
- University of Rome Tor VergataStudy chair
Drugs studied
Indications studied
- Aphasia
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Communication Disorders
- Dementia
- Language Disorders
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Speech Disorders
- Aphasia, Primary Progressive
- Neurodegenerative Diseases
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Pick Disease of the Brain
- Proteostasis Deficiencies
- Frontotemporal Lobar Degeneration
- TDP-43 Proteinopathies
- Frontotemporal Dementia
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.